HepaRG® Cells Publication List
Cytochromes P450
Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C,
Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear
receptors in human hepatoma HepaRG cells. Drug Metab Dispos. 3475-83 (2006).
Kanebratt KP, Andersson TB. Evaluation of HepaRG cells as an in vitro model for human
drug metabolism studies.Drug Metab Dispos.36 1444-52 (2008).
Kanebratt KP, Andersson TB. HepaRG cells as an in vitro model for evaluation of
cytochrome P450 induction in humans. Drug Metab Dispos. 36137-45 (2008).
Lambert CB, Spire C, Claude N, Guillouzo A. Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol.234 345-60 (2009).
Lambert CB, Spire C, Renaud MP, Claude N, Guillouzo A. Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 23 466-75 (2009).
Turpeinen M, Tolonen A, Chesne C, Guillouzo A, Uusitalo J, Pelkonen O. Functional Expression, Inhibition and Induction of CYP Enzymes in HepaRG cells. Toxicol In Vitro. 2009 Mar 25. [Epub ahead of print]
McGinnity DF, Zhang G, Kenny J, Hamilton G, Otmani S, Stams K, Haney S, Brassil P, Stresser DM, Riley RJ. Evaluation of multiple in vitro systems for assessment of CYP3A4 Induction in Drug Discovery: Human hepatocytes, PXR reporter gene, Fa2N-4 and HepaRG cells. Drug Metab Dispos. 2009 Mar 23. [Epub ahead of print]
Drug Transporters
Barraud L, Merle P, Soma E, Lefrançois L, Guerret S, Chevallier M, Dubernet C, Couvreur P,
Trépo C, Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-loading into
nanoparticles for hepatocellular carcinoma cells in vitro and in vivo.J Hepatol. 42 736-
43 (2005).
Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O. Functional
expression of sinusoidal and canalicular hepatic drug transporters in the differentiated
human hepatoma HepaRG cell line. Eur J Pharm Sci. 28109-17 (2006).
Le Vee M, Gripon P, Stieger B, Fardel O. Down-regulation of organic anion transporter
expression in human hepatocytes exposed to the proinflammatory cytokine interleukin
1beta. Drug Metab Dispos. 36 217-22 (2008).
Genotoxicity, toxicity, liver metabolism
Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. The human
hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism
and toxicity of xenobiotics. Chem Biol Interact. 168 66-73 (2007).
Kirkland D, Pfuhler S, Tweats D, Aardema M, Corvi R, Darroudi F, Elhajouji A, Glatt H,
Hastwell P, Hayashi M, Kasper P, Kirchner S, Lynch A, Marzin D, Maurici D, Meunier JR,
Müller L, Nohynek G, Parry J, Parry E, Thybaud V, Tice R, van Benthem J, Vanparys P,
White P. How to reduce false positive results when undertaking in vitro genotoxicity
testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM
Workshop.Mutat Res. 628 31-55 (2007).
Guillouzo A, Guguen-Guillouzo C. Evolving concepts in liver tissue modeling and
implications for in vitro toxicology. Expert Opin Drug Metab Toxicol. 4 1279-1294 (2008).
Aninat C, Seguin P, Descheemaeker PN, Morel F, Malledant Y, Guillouzo A. Catecholamines induce an inflammatory response in human hepatocytes. Crit Care Med.36 848-54 (2008).
Jossé R, Aninat C, Glaise D, Dumont J, Fessard V, Morel F, Poul JM, Guguen-Guillouzo C,
Guillouzo A. Long-term functional stability of human HepaRG hepatocytes and use for
chronic toxicity and genotoxicity studies. Drug Metab Dispos. 361111-8 (2008).
Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F. Differential toxic
effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes.
Toxicol In Vitro. 22 632-42 (2008).
Hepatic Progenitor Cells (HPC)
Parent R, Marion MJ, Furio L, Trépo C, Petit MA. Origin and characterization of a human
bipotent liver progenitor cell line. Gastroenterology. 126 1147-56 (2004).
Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, Gripon P, Kremsdorf D,
Guguen-Guillouzo C, Corlu A. Transdifferentiation of hepatocyte-like cells from the
human hepatoma HepaRG cell line through bipotent progenitor. Hepatology. 45 957-67
(2007).
Maire M, Parent R, Morand AL, Alotte C, Trépo C, Durantel D, Petit MA. Characterization
of the double-stranded RNA responses in human liver progenitor cells. Biochem Biophys
Res Commun. 368 556-62 (2008).
Parent R, Beretta L. Translational control plays a prominent role in the hepatocytic
differentiation of HepaRG liver progenitor cells. Genome Biol. 9R19 (2008).
Hepatitis B Virus
Sureau C, Fournier-Wirth C, Maurel P. Role of N glycosylation of hepatitis B virus
envelope proteins in morphogenesis and infectivity of hepatitis delta virus.J Virol. 77 19-
23 (2003).
Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C,
Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus.
Proc Natl Acad Sci U S A. 99 15655-60 (2002).
Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated
peptides derived from the large viral surface protein. J Virol. 791613-22 (2005).
Jaoudé GA, Sureau C. Role of the antigenic loop of the hepatitis B virus envelope proteins
in infectivity of hepatitis delta virus. J Virol.79 10460-6 (2005).
Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnölzer M, Urban S. Characterization of
a hepatitis B and hepatitis delta virus receptor binding site. Hepatology. 43 750-60
(2006).
Rabe B, Glebe D, Kann M. Lipid-mediated introduction of hepatitis B virus capsids into
nonsusceptible cells allows highly efficient replication and facilitates the study of early
infection events.J Virol. 80 5465-73 (2006).
Blanchet M, Sureau C. Analysis of the cytosolic domains of the hepatitis B virus envelope
proteins for their function in viral particle assembly and infectivity.
J Virol. 80 11935-45 (2006).
Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry.
World J Gastroenterol. 13 22-38 (2007).
Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface
protein-dependent binding to heparan sulfate proteoglycans. Hepatology. 46 1759-68
(2007).
Lucifora J, Durantel D, Belloni L, Barraud L, Villet S, Vincent IE, Margeridon-Thermet S,
Hantz O, Kay A, Levrero M, Zoulim F. Initiation of hepatitis B virus genome replication
and production of infectious virus following delivery in HepG2 cells by novel
recombinant baculovirus vector. J Gen Virol. 891819-28 (2008).
Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Dény P, Zoulim F. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology. 136 168-176 (2009).
Hantz O, Parent R, Durantel D, Gripon P, Guguen-Guillouzo C, Zoulim F. Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J Gen Virol.90 127-35 (2009).
Narayan R, Gangadharan B, Hantz O, Antrobus R, García A, Dwek RA, Nicole Z. Proteomic analysis of HepaRG cells: a novel cell line that supports hepatitis B virus infection. J Proteome Res. 8 118-2 (2009).
Vincent IE, Lucifora J, Durantel D, Hantz O, Chemin I, Zoulim F, Trepo C. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.Antivir Ther14 131-5 (2009).
Hepatitis Delta
Abou-Jaoudé G, Sureau C. Entry of hepatitis delta virus requires the conserved cysteine
residues of the hepatitis B virus envelope protein antigenic loop and is blocked by
inhibitors of thiol-disulfide exchange. J Virol. 8113057-66 (2007).
Hepatocytic differentiation
Parent R, Kolippakkam D, Booth G, Beretta L. Mammalian target of rapamycin activation
impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and
hepatocellular growth.Cancer Res. 67 4337-45 (2007).
Iron metabolism
Troadec MB, Glaise D, Lamirault G, Le Cunff M, Guérin E, Le Meur N, Détivaud L, Zindy
P, Leroyer P, Guisle I, Duval H, Gripon P, Théret N, Boudjema K, Guguen-Guillouzo C,
Brissot P, Léger JJ, Loréal O. Hepatocyte iron loading capacity is associated with
differentiation and repression of motility in the HepaRG cell line. Genomics.87 93-103
(2006).
Lipid metabolism
Antoun J, Amet Y, Simon B, Dréano Y, Corlu A, Corcos L, Salaun JP, Plée-Gautier E.
CYP4A11 is repressed by retinoic acid in human liver cells. FEBS Lett. 5803361-7
(2006).
Nagasawa M, Akasaka Y, Ide T, Hara T, Kobayashi N, Utsumi M, Murakami K. Highly
sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated
receptor alpha (PPARalpha) agonist in human hepatoma cells. Biochem Pharmacol.74
1738-46 (2007).
Antoun J, Goulitquer S, Amet Y, Dreano Y, Salaun JP, Corcos L, Plée-Gautier E. CYP4F3B
is induced by PGA1 in human liver cells: a regulation of the 20-HETE synthesis.J Lipid
Res.49 2135-41 (2008).
